A multi-award-winning pharmaceutical executive, Terrell “Terry” Herring serves as president of commercial operations for Mission Pharmacal Company, a privately held pharmaceutical firm. Terrell “Terry” Herring plays a leading role in the company’s various subsidiaries including serving as president of Alamo Pharma Services. Alamo Pharma provides integral solutions to biotech and pharmaceutical firms which successfully usher their products to market in a cost-effective manner. The company recently announced a strategic partnership with Thingee Corporation, a life sciences-focused software company, wherein Alamo will utilize Thingee’s new iDetail™ enterprise content delivery platform. Specifically designed for iPad, iDetail enables Alamo’s sales representatives to rapidly access their latest audio/video files and presentations, as well as other sales and detailing aids. The software platform features touch interface and outstanding visual display while also having the capability to collect detailing call data in real time backed by powerful analytics. This platform will help representatives to engage physicians and their office staff members in a more lively and effective way, leading to increased sales team productivity.
0 Comments
Terrell Herring serves as president of Alamo Pharma Services, a subsidiary company of Mission Pharmacal. At the latter firm, he additionally assists in directing strategic decision-making as commercial operations president. Terrell Herring and Alamo Pharma recently announced the company’s participation in a major Washington, DC conference designed to better acquaint attendees with how government regulatory processes affect innovations in the pharmaceutical industry. Alamo Pharma served as a sponsor of the FDA/CMS Summit, held toward the close of 2017. In addition, the company’s chief operating officer Peter Marchesini spoke as a member of a panel discussing the future of product-related communications, with specific reference to off-label developments. Mr. Marchesini’s panel group was moderated by journalist M. Nielsen Hobbs, whose decades of experience have informed his coverage of the pharmaceutical industry. The panel discussed the ongoing needs for training of company representatives in product knowledge and compliance requirements, and for overall fairness in labeling. KNect365, part of the Informa family of companies, hosted the summit, which also provided corporate leaders the opportunity to connect directly with regulators on issues involving formulary protocols. A former CEO and director of InVentiv Health, Terrell (Terry) Herring assumed the role of president of Mission Pharmacal Company in 2010. The following year, Terrell Herring also began serving as president of Alamo Pharma Services, a recruitment and talent acquisition company specializing in the pharmaceutical and biotech sector.
In February 2017, Alamo announced a partnership with Napo Pharmaceuticals, Inc., to create a national sales team for the company's new FDA-approved drug Mytesi, which provides relief from noninfectious diarrhea in people with HIV who are on antiretroviral therapies. Napo Pharmaceuticals and its partner company, Jaguar Animal Health, Inc., estimate a potential U.S. market value of more than $100 million in annual sales for the drug, and Alamo will significantly help them reach that target. Mytesi's active pharmaceutical ingredient is crofelemer, an anti-secretory agent harvested from the rain forest. The twice-daily tablets yielded encouraging results in clinical trials with HIV-positive patients, showing a reduction in the average number of watery stools per week from 20 to less than two. |
AuthorTerrell Herring began working at Mission Pharmacal Company in 2010, bringing more than 25 years of experience in the pharmaceutical industry to his role as President of Commercial Operations. Archives
February 2018
Categories
All
|